Igc pharma announces patient enrollment at toronto's baycrest in phase 2 trial investigating igc-ad1

- company expands phase 2 trial to canada - potomac, md / accesswire / october 17, 2024 / igc pharma, inc (nyse american:igc) ("igc" or the "company"), today announced enrollment of patients at the baycrest academy for research and education in toronto, ontario, canada, as part of the company's ongoing phase 2 trial investigating igc-ad1 as a treatment for agitation in alzheimer's dementia. agitation affects between 40-80% of alzheimer's patients and is a major driver of long-term hospitalization, increased mortality, and higher use of medication.
IGC Ratings Summary
IGC Quant Ranking